Натуральные антибиотики. Природная альтернатива фармакологическим препаратам

Dankwa, Kwabena. Evaluation of antimalarial activity of four (4) Cryptolepis sanguinolenta based herbal preparations on Plasmodium berghei in mice. Thesis, Kwame Nkruma University of Science and Technology (Ghana), 2006. http://dspace.knust.edu.gh/dspace/handle/123456789/1590.

Dassonneville, L., et al. Cytotoxicity and cell cycle effects of the plant alkaloids cryptolepine and neocryptolepine: relation to drug-induced apoptosis. Eur J Pharmacol 409, no. 1 (2000): 9–18.

Gibbons, S., et al. Cryptolepine hydrochloride: a potent antimycobacterial alkaloid derived from Cryptolepis sanguinolenta. Phytother Res 17, no. 4 (2003): 434–36.

Grycová, Lenka. Applications of NMR to study structures of natural compounds. PhD thesis, Masaryk University, 2010. http://is.muni.cz/th/12679/prif_d/PhD_thesis_LG.pdf.

Guittat, L., et al. Interactions of cryptolepine and neocryptolepine with unusual DNA structures. Biochemie 85, no. 5 (2003): 535–47.

Hadden, C. E., et al. 11-isopropylcryptolepine: a novel alkaloid isolated from Cryptolepis sanguinolenta characterized using submicro NMR techniques. J Nat Prod 62, no. 2 (1999): 238–40.

Humenuik, R., et al. Cytotoxicity and cell cycle effects of novel indolo[2,3-b]quinoline derivatives. Oncol Res 13, no. 5 (2003): 269–77.

Iwu, Maurice M. The Associate Program on Ethnobiology, Socio-Economic Value Assessment and Community Based Conservation. Report DAMD17–99-2–9025, prepared for the U.S. Army Medical Research and Materiel Command, Fort Detrick, Md., October 2000. http://www.dtic.mil/cgi-bin/GetTRDoc?Location=U2&doc=GetTRDoc.pdf&AD=ADA406251.

Jansen, P. C. M., and Schmelzer, G. H. Cryptolepis sanguinoleta (Lindl.) Schltr. Record from Protabase database, ed. G. J. H. Grubben and O. A. Denton (PROTA: Plant Resources of Tropical Africa/Resources vegetales de l’Afrique tropicale). Wageningen, Netherlands. http://database.prota.org/search.htm (accessed November 18, 2010).

Jaromin, A., et al. Liposomal formulation of DIMIQ, potential antitumor indolo[2,3-b] quinoline agent and its cytotoxicity on hepatoma Morris 5123 cells. Drug Deliv 15, no. 1 (2008): 49–56.

Jonckers, T. H., et al. Synthesis, cytotoxicity, and antiplasmodial and antitrypanosomal activity of new neocryptolepine derivatives. J Med Chem 45, no. 16 (2002): 3497–508.

Kaul, A., et al. Immunopotentiating properties of Cryptolepis buchanani root extract. Phytother Res 17, no. 10 (2003): 1140–44.

Laupattarakasem, P., et al. An evaluation of the activity related to inflammation of four plants used in Thailand to treat arthritis. J Ethnopharmacol 85, no. 2–3 (2003): 207–15.

Laupattarakasem, P., et al. In vitro and in vivo anti-inflammatory potential of Cryptolepis buchanani. J Ethnopharmacol 108, no. 3 (2006): 349–54.

Luo, J., et al. Cryptolepis sanguinolenta: an ethnobotanical approach to drug discovery and the isolation of a potentially useful new antihyperglycaemic agent. Diabet Med 15, no. 5 (1998): 367–74.

Luo, J., et al. Hypoglycemic agent from cryptolepis. U.S. Patent 5,629,319, filed June 6, 1995, and issued May 13, 1997.

Maurya, et al. Pharmaceutical composition comprising extract from plant Cryptolepis buchanani for tea. U.S. Patent 6,548,086, filed December 18, 2001, and issued April 15, 2003.

Mills-Robertson, F. C., et al. In vitro antimicrobial activity of Cryptolepis sanguinolenta (Periplocaceae). Afr J Pharm Pharmacol 3, no. 10 (2009): 476–80.

Mtshemla, Vathiswa. Synthesis of 2,3-diaryl-4-methoxyquinolines via palladium-catalyzed cross coupling reactions. Master’s thesis, University of South Africa, May 2008. http://uir.unisa.ac.za/bitstream/handle/10500/2275/dissertation.pdf?sequence=1.

Noamesi, B. K., et al. Studies on cryptolepine. Planta Med 48, no. 5 (1983): 48–51.

Obua, C., et al. Antimalarial activity of some plants used in traditonal medicine in Uganda. E C Afr J Pharma Sci 5, no. 2 (2002): 1.

Olajide, O. A., et al. Anti-inflammatory properties of cryptolepine. Phytother Res 23, no. 10 (2009): 1421–25.

Olajide, O. A., et al. Synthetic cryptolepine inhibits DNA binding of NF-kappaB. Bioorg Med Chem 15, no. 1 (2007): 43–49.

Oluwafemi, A. J., et al. Evaluation of cryptolepine and huperzine derivatives as lead compounds towards new agents for the treatment of human African trypanosomiasis. Nat Prod Commun 4, no. 2 (2009): 193–98.

Otsyina, Hope R. Toxicological evaluation of Cryptolepis sanguinolenta, Momordica charantia and Euphorbia hirta in rats. Thesis, Kwame Nkruma University of Science and Technology (Ghana), 2008. http://dspace.knust.edu.gh:8080/jspui/handle/123456789/885.